| 4.97 0.18 (3.76%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.92 | 1-year : | 9.15 |
| Resists | First : | 5.93 | Second : | 7.83 |
| Pivot price | 3.79 |
|||
| Supports | First : | 2.84 | Second : | 2.37 |
| MAs | MA(5) : | 4.18 |
MA(20) : | 3.8 |
| MA(100) : | 4.6 |
MA(250) : | 7.57  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 54.5 |
D(3) : | 54.2 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 15.89 | Low : | 2.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRE ] has closed It is unclear right now based on current values. 75% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.36 - 5.38 | 5.38 - 5.4 |
| Low: | 4.31 - 4.33 | 4.33 - 4.34 |
| Close: | 4.93 - 4.97 | 4.97 - 4.99 |
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Mon, 08 Apr 2024
Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues - Simply Wall St
Mon, 01 Apr 2024
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Tue, 26 Mar 2024
Healthcare Stocks Moving Up and Down Tuesday: STOK, NUVB, RVPH, CRDL, EQ, PRE, BLRX, GLUE - InvestorsObserver
Sat, 09 Mar 2024
When Will Prenetics Global Limited (NASDAQ:PRE) Become Profitable? - Simply Wall St
Fri, 09 Feb 2024
Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to ... - PR Newswire Asia
Mon, 20 Nov 2023
Prenetics Announces Third Quarter 2023 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | 4.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.9 |
| Profit Margin | -288.5 % |
| Operating Margin | -211.4 % |
| Return on Assets (ttm) | -10.7 % |
| Return on Equity (ttm) | -24.9 % |
| Qtrly Rev. Growth | -89.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.04 |
| EBITDA (p.s.) | -4.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 1.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.29 |
| Price to Sales | 2.42 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|